SCHEMBL4769800

SCHEMBL4769800

CCn1c(=O)[nH]c(C)c([N+](=O)[O-])c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
MAPT P10636 5/20 0.42
LMNA P02545 4/20 0.42
HTT P42858 3/20 0.42
NPC1 O15118 1/20 0.42
MITF O75030 1/20 0.42
AGTR1 P30556 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TLR9 Q9NR96 1/20 0.42
CYP1A2 P05177 3/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE4A P27815 1/20 0.37
ADORA2A P29274 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767502 0.87 ADORA2B (0.40) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL4766186 0.84 ADORA2B (0.43) ALDH1A1MAPTLMNANPSR1GAA
SCHEMBL30799096 0.83 ALDH1A1 (0.49) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL4771513 0.82 KDM4E (0.42) ALDH1A1MAPTLMNANPSR1GAA
SCHEMBL4762675 0.77 PKM (0.53) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL4772758 0.76 ADORA2B (0.50) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL4762293 0.75 KMT2A (0.48) ALDH1A1GAASMN1; SMN2POLBMEN1
SCHEMBL4765819 0.75 HSPD1 (0.42) ALDH1A1MAPTHTTRAB9ATLR9
SCHEMBL4767367 0.73 HSPD1 (0.41) ALDH1A1MAPTLMNAHTTNPC1
SCHEMBL4765767 0.73 ALDH1A1 (0.53) ALDH1A1MAPTHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678181-B1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-12-31 EP disclosed
EP-1678181-B1 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2008-12-31 EP disclosed
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 1178/4885MAPT 4503/4885LMNA 4664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.